![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ABHD17B |
Gene summary for ABHD17B |
![]() |
Gene information | Species | Human | Gene symbol | ABHD17B | Gene ID | 51104 |
Gene name | abhydrolase domain containing 17B, depalmitoylase | |
Gene Alias | C9orf77 | |
Cytomap | 9q21.13 | |
Gene Type | protein-coding | GO ID | GO:0002084 | UniProtAcc | Q5VST6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51104 | ABHD17B | CA_HPV_2 | Human | Cervix | CC | 3.64e-02 | 1.65e-01 | 0.0391 |
51104 | ABHD17B | CCI_1 | Human | Cervix | CC | 4.19e-08 | 5.38e-01 | 0.528 |
51104 | ABHD17B | CCI_2 | Human | Cervix | CC | 7.91e-08 | 8.43e-01 | 0.5249 |
51104 | ABHD17B | CCI_3 | Human | Cervix | CC | 4.10e-02 | 2.74e-01 | 0.516 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![]() | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:01060277 | Cervix | CC | neuron projection organization | 21/2311 | 93/18723 | 4.10e-03 | 2.54e-02 | 21 |
GO:1905668 | Cervix | CC | positive regulation of protein localization to endosome | 5/2311 | 11/18723 | 6.92e-03 | 3.74e-02 | 5 |
GO:19038286 | Cervix | CC | negative regulation of cellular protein localization | 24/2311 | 117/18723 | 8.10e-03 | 4.23e-02 | 24 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABHD17B | SNV | Missense_Mutation | c.535N>T | p.Leu179Phe | p.L179F | Q5VST6 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
ABHD17B | SNV | Missense_Mutation | c.563N>A | p.Val188Asp | p.V188D | Q5VST6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3693-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ABHD17B | SNV | Missense_Mutation | c.392N>A | p.Gly131Asp | p.G131D | Q5VST6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3973-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | bevacizumab | SD | |
ABHD17B | SNV | Missense_Mutation | novel | c.691C>A | p.His231Asn | p.H231N | Q5VST6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ABHD17B | SNV | Missense_Mutation | novel | c.587C>T | p.Ser196Leu | p.S196L | Q5VST6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ABHD17B | SNV | Missense_Mutation | c.212C>T | p.Thr71Ile | p.T71I | Q5VST6 | protein_coding | tolerated(0.45) | benign(0.187) | TCGA-A5-A0GJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
ABHD17B | SNV | Missense_Mutation | novel | c.486N>C | p.Glu162Asp | p.E162D | Q5VST6 | protein_coding | tolerated(0.14) | benign(0.026) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ABHD17B | SNV | Missense_Mutation | rs373175774 | c.733G>A | p.Ala245Thr | p.A245T | Q5VST6 | protein_coding | tolerated(0.21) | benign(0.103) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABHD17B | SNV | Missense_Mutation | novel | c.611N>G | p.Asp204Gly | p.D204G | Q5VST6 | protein_coding | tolerated(0.49) | benign(0.011) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABHD17B | SNV | Missense_Mutation | rs373175774 | c.733N>A | p.Ala245Thr | p.A245T | Q5VST6 | protein_coding | tolerated(0.21) | benign(0.103) | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |